| Wissenschaftl. Titel | A Phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations. |
| Erkrankung |
Lunge:
Lungenkrebs:
Nicht kleinzelliges Lungenkarzinom (NSCLC) - Erstlinie
|
| Molekularer Marker |
EGFR |
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Ein- und Ausschlusskriterien |
erstellt 11.06.2025 Admin07
geändert 11.06.2025 Admin07